BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 29223572)

  • 1. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
    Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
    Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
    Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
    Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
    Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
    Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin potentiates the antitumor activity of Paclitaxel in rat glioma C6 cells.
    Fratantonio D; Molonia MS; Bashllari R; Muscarà C; Ferlazzo G; Costa G; Saija A; Cimino F; Speciale A
    Phytomedicine; 2019 Mar; 55():23-30. PubMed ID: 30668434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
    Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
    Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
    Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
    J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
    Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
    Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rutin inhibits carfilzomib-induced oxidative stress and inflammation via the NOS-mediated NF-κB signaling pathway.
    Al-Harbi NO; Imam F; Al-Harbi MM; Al-Shabanah OA; Alotaibi MR; As Sobeai HM; Afzal M; Kazmi I; Al Rikabi AC
    Inflammopharmacology; 2019 Aug; 27(4):817-827. PubMed ID: 30600471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
    Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
    J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
    Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
    Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
    Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
    Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
    Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
    Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
    Nabissi M; Morelli MB; Offidani M; Amantini C; Gentili S; Soriani A; Cardinali C; Leoni P; Santoni G
    Oncotarget; 2016 Nov; 7(47):77543-77557. PubMed ID: 27769052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
    Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
    Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway.
    Takeda T; Tsubaki M; Kino T; Kawamura A; Isoyama S; Itoh T; Imano M; Tanabe G; Muraoka O; Matsuda H; Satou T; Nishida S
    Int J Oncol; 2016 Jun; 48(6):2704-12. PubMed ID: 27035859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species.
    Sankpal UT; Nagaraju GP; Gottipolu SR; Hurtado M; Jordan CG; Simecka JW; Shoji M; El-Rayes B; Basha R
    Oncotarget; 2016 Jan; 7(3):3186-200. PubMed ID: 26672603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro.
    Ghoneum M; Gollapudi S
    Neoplasma; 2011; 58(2):118-23. PubMed ID: 21275460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.